BioSpace News Archive

KaliVir Immunotherapeutics, Inc. announced the presentation of new data on its lead pre-clinical candidate VET3-TGI at the American Society of Gene & Cell Therapy 26th Annual Meeting.

Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy 26th Annual Meeting in Los Angeles.

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, will present first-of-its-kind preclinical research from a collaboration study showing homing and engraftment of B cells in non-human primates with intact immune systems.

Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, presented new data for its gene editing programs during the 26th American Society of Gene + Cell Therapy Annual Meeting.

Rocket Pharmaceuticals, Inc. announced positive data from the Pyruvate Kinase Deficiency, Fanconi Anemia, Severe Leukocyte Adhesion Deficiency-I and Danon Disease clinical programs and PKP2-arrhythmogenic cardiomyopathy preclinical program presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy in Los Angeles, California.

2seventy bio, Inc. announced late-breaking results from the ongoing Phase 1 PLAT-08 trial, in collaboration with Seattle Children’s Therapeutics, evaluating SC-DARIC33 in relapsed or refractory pediatric and young adult AML patients, as well as an oral presentation evaluating regulated IL-15 production combined with DARIC33 activation for anti-AML potency.

Reviva Pharmaceuticals Holdings, Inc. announced the Company has joined Webull’s Corporate Communications Service Platform.

Intercept Pharmaceuticals, Inc. today announced that NASDAQ has halted trading of the company’s common stock.

TELA Bio, Inc today announced it will be hosting its next cadaver lab on May 19 in Tampa, Florida.

Kymera Therapeutics, Inc. has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253.